Data suggest radium-223 and PSMA-targeted radionuclides are well tolerated in prostate cancer

“We look forward to the optimization of these drugs,” says Scott T. Tagawa, MD, MS, FACP.

In this video, Scott T. Tagawa, MD, MS, FACP, discusses the main points of the presentation, “Therapeutic radiopharmaceuticals: Past, present, and future,” which was given recently at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.